India Globalization Capital, Inc. IGC revealed Thursday that it has obtained a patent from the United States Patent and Trademark Office for the treatment of Alzheimer’s disease. The patent (#11,065,225) is named “Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s Disease.”
The Potomac, Maryland-based cannabis company noted the initial patent submission was filed by the University of South Florida in August 2016. The following year in May, IGC signed an exclusive agreement with the University in relation to the patent application
and connected research on Alzheimer’s disease.
The obtained patent is related to the company’s proprietary formulation - IGC-AD1, which is earmarked to assist in the treatment of patients with Alzheimer’s. The formulation is the subject of IGC’s Phase 1 clinical trial.
IGC recently disclosed the completion of its placebo-controlled Multiple Ascending Dose (MAD) Phase 1 trial for determining the safety of IGC-AD1 that uses THC on patients with Alzheimer’s disease.
Price Action
India Globalization Capital shares were trading 132% higher at $3.44 per share at the time of writing Thursday morning.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!